New study monitors SPINRAZA's effect on movement in adults with spinal muscular atrophy

NCT ID NCT04159987

First seen Dec 08, 2025 · Last updated May 14, 2026 · Updated 23 times

Summary

This study follows 20 adults with spinal muscular atrophy (SMA) type II who are already taking SPINRAZA, a medication given via spinal injection. Researchers will measure changes in motor function, like sitting, standing, and arm movement, over 27 months. The goal is to see how well the drug maintains or improves movement in this group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • APHP

    Paris, Île-de-France Region, 94000, France

  • CHRU de Lille

    Lille, Hauts-de-France, 59000, France

  • CHU de Lyon

    Lyon, Auvergne-Rhône-Alpes, 69677, France

  • CHU de Montpellier

    Montpellier, Occitanie, 34090, France

  • CHU de Nice

    Nice, Provence-Alpes-Côte d'Azur Region, 06000, France

  • CHU de Toulouse

    Toulouse, Occitanie, 31059, France

  • Hopital de la Timone - APHM

    Marseille, Provence-Alpes-Côte d'Azur Region, 13005, France

Conditions

Explore the condition pages connected to this study.